ProQR Therapeutics N.V. Financial Performance Review
Company Announcements

ProQR Therapeutics N.V. Financial Performance Review

ProQR (PRQR) has released an update.

ProQR Therapeutics N.V. has reported a decrease in total assets from €137,883 thousand at the end of 2023 to €118,051 thousand by June 30, 2024, while equity attributable to owners decreased from €41,390 thousand to €32,854 thousand in the same period. The company’s financial performance shows a loss for the six-month period ending June 30, 2024, with a total comprehensive income of negative €10,074 thousand compared to negative €17,044 thousand in the previous year. These financial results reflect the ongoing costs and challenges faced by the company in its operations.

For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyProQR Therapeutics price target raised to $10 from $5 at H.C. Wainwright
TheFlyProQR Therapeutics price target raised to $4 from $2.50 at Chardan
TipRanks Auto-Generated NewsdeskProQR Therapeutics Shows Revenue Growth Amid Financial Challenges
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App